Aclaris Therapeutics (ACRS) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 99.5% versus a loss of 5.8%. Over five years, DRUG leads with a +40.0% price change compared with -77.5% for ACRS. Aclaris Therapeutics is the larger company by market cap ($560.8 million vs $532.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | DRUG |
|---|---|---|
| Share price | $3.81 | $54.01 |
| Market cap | $560.83M | $532.76M |
| 1-day change | +0.53% | +3.87% |
| YTD return | +25.91% | -33.37% |
| 1-year return | +99.47% | -5.80% |
| 5-year return | -77.45% | +39.97% |
| EPS (TTM) | $-0.58 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $123.75 |
| 52-week low | $1.74 | $47.23 |
| Distance from 52-week high | -42.27% | -56.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +167.19% | +181.37% |
| Average volume | 2.59M | 159.01K |
| Shares outstanding | 147.20M | 9.86M |
| Employees | 69 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed DRUG by 105.3 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ACRS vs DRUG FAQ
Which is bigger, Aclaris Therapeutics or Bright Minds Biosciences?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $560.83M compared with $532.76M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, ACRS or DRUG?
ACRS returned +99.47% over the past 12 months, compared with -5.80% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.